2015

• · Released influenza test kit
• · Selected as KOSDAQ listed weekly securities company (High Investment Securities)
• · kGMP certification (Class IV), medical device sales business, telecommunication sales business

2014

• · Chinese product registration (three types of cardiac quantitative analysis reagents); Tnl, BNP, Cardiac 3-1
• · Entered into circulation markets such as marts/convenience stores (pregnancy/ovulation diagnosis reagent)
• · Converted medical device law enforcement related products (82 items) medical device import business license (No. 3482)
• · Proclaimed WHO Malaria RDT5 (excellent performance among all Malaria pf/pan items)

2013

• · Selected as a "good job company" by the Ministry of Employment and Labor
• · Selected as a creative company by IB
• · Signed WHO LTA (long term agreement; Malaria pf/pv test) contract
• · Selected for P300 project (Ministry of Trade, Industry and Energy, export support project)
• · Proclaimed WHO Malaria RDT4 (No. 1 performance among all Malaria pf/pv products)

2012

• · Obtained foreign manufacturer certification from Japan Food and Drug Administration (AG10300117)
• · Acquired drug import business license
• · Launched urine chemical analysis equipment and reagents
• · Released Dengue antigen test kit

2011

• · Registered as UNPD vendor (UN)
• · Released Dengue antibody test kit
• · Registered as UNICEF vendor (UN)
• · Registered as KOICA Vendor (Korea International Cooperation Agency)
• · Designated as a promising small and medium export business (Small and Medium Business Administration)
• · Selected as a leading company for P300 international organization procurement (KOTRA, Korea Import & Export Corporation)
• · U.S. patent registration (diagnostic device using similar structure protein ratio measurement)
• · Selected as Gyeonggi-do e-frontier company
• · Selected as New Exporters 300’’ company (Korea International Trade Association)

2010

• · Selected as a participating company in the Export SME 500 Program (Small and Medium Business Administration)
• · Released myocardial infarction quantitative analysis reagent (HUBI Cardiac 3in1)

2009

• · Released POCT immunoquantitative analysis equipment (HUBI-QUAN pro)
• · Acquired medical device manufacturing license (kFDA)

2008

• · Changed CEO (Cha Jeong-hak)
• · US patent registration of abnormal pregnancy test kit (Inex screen) (Registration number: 7332350

2007

• · Certified as INNOBIZ (No. 7025-2254, Class A)
• · Relocated the head office (#504 Shinwon Vision Tower, 898 Hogye-dong, Dongan-gu, Anyang-si, Gyeonggi-do)

2006

• · PCT international application (Diagnostic device using similar structure protein ratio measurement PCT/KR20060001927)
• · China patent registration of abnormal pregnancy test kit (Inex screen) (Registration number: China ZL01814071.8)
• · Obtained IS013485

2005

• · SME technology innovation competition technology innovation award (acute myocardial infarction test kit)
• · Signed a joint R&D agreement with Yuhan Corporation

2004

• · Confirmed as a venture company (No. 041622021-1-00745)
• · ISO Certification (9001:2000/KS A 9001:2001 DAS Certification)

2003

• · Released abnormal pregnancy test kit
• · Established Central R&D Center, launched acute myocardial infarction test kit

2002

• · CLEAN workplace certification (Korea Occupational Safety and Health Agency)
• · Started trading business (trade business serial number-21059098)

2001

• · Abnormal pregnancy test kit (Inex screen) PCT application (PCT/KR01/01365)

2000

• · Acquired pharmaceutical manufacturing business (kFDA)
• · Relocated the head office (345-1 Dangjeong-dong, Gunpo-si, Gyeonggi-do)
• · Established the company (10F, Goun Advanced Science and Technology Research Institute, Suwon University, San 2-2, Wau-ri, Bongdam-eup, Hwaseong-gun, Gyeonggi-do)